<DOC>
	<DOCNO>NCT00710697</DOCNO>
	<brief_summary>The purpose study investigate effect , , picoplatin heart rhythm .</brief_summary>
	<brief_title>Cardiac Safety Assessment Study Picoplatin Solid Tumors</brief_title>
	<detailed_description>Phase 1 2 study demonstrate picoplatin , next-generation platinum analogue design avoid drug resistance , activity administer IV variety cancer . Preclinical clinical study indicate picoplatin may effective platinum refractory resistant cancer . Preclinical data beagle dog show picoplatin effect cardiovascular function , include QT interval . In cumulative human trial experience , cardiovascular serious adverse event occur consistent event expect patient advanced malignant disease suggest propensity toward drug-related serious ventricular arrhythmia sudden death . The purpose trial conduct formal study specifically evaluate effect picoplatin QT/QTc interval measure ECG , correlate QTcF interval plasma total ultrafilterable platinum concentration . This study also conduct ensure safety picoplatin regard QT/QTc interval . Patients choose participate study also give opportunity continue receive picoplatin limited toxicity disease progression .</detailed_description>
	<criteria>Documented histological cytological diagnosis nonhematological malignancy . Subjects , opinion investigator , treatment single agent picoplatin appropriate . 18 year age old . ECOG performance status 02 . An acceptable screening ECG . The following laboratory value : ANC ≥ 1500 cells/mm3 ( without use myeloid growth factor ) . Hemoglobin ≥ 10.0 g/dL ( may achieve transfusion growth factor ) . Platelet count ≥ 100,000/mm3 ( without platelet transfusion past 10 day ) . Serum creatinine ≤ 1.5 x ULN . Total bilirubin ≤ 1.5 x ULN . AST/SGOT ALT/SGPT ≤ 2.5 x ULN ( 5.0 x ULN event document hepatic tumor involvement ) . Serum potassium magnesium within institutional normal limit . PT , aPTT ≤ 1.2 x ULN . Recovery period ≥ 4 week since major surgery , chemotherapy ( ≥ 6 week treatment mitomycin nitrosourea ) , biological therapy , investigational therapy change usage `` alternative therapy '' . Recovery period ≥ 2 week since radiation therapy . Willing , available able comply protocol requirement include dietary schedule restriction . Written inform consent obtain prior screen procedure . Symptomatic uncontrolled brain metastasis . Use conventional granulocyte growth factor within precede 10 day pegfilgrastim within past 21 day . Any concurrent severe and/or uncontrolled medical condition could compromise participation study . For example , Unresolved toxicities prior treatment &gt; Grade 1 ( alopecia ) . Clinically significant infection . Known viral infection hepatitis B C HIV . Clinically significant psychiatric illness . Any systemic localized disease therapy likely interfere tolerance chemotherapy requirement study participation . History unexplained syncope within last two month family history sudden unexplained death . Cardiac contraindication study participation , include : History serious cardiac disease , define myocardial infarction within three month enrollment , congestive heart failure classify New York Heart Association Class III IV , clinically significant cardiac arrhythmia , poorly control unstable angina electrocardiographic evidence acute ischemia . Implantable pacemaker automatic implantable cardioverter defibrillator . Congenital long QT syndrome family history long QT syndrome . If male , QTc &gt; 450 m ; female , QTc &gt; 460 ms. PR duration &gt; 240 m ; QRS &gt; 110 ms. Complex arrhythmia ( significant ventricular tachycardia , Mobitz block , bifascicular AV block ) screening ECG . Atrial fibrillation flutter . Complete leave bundle branch block ; use obligate pacemaker . Current use anticoagulant antiplatelet drug , include aspirin , warfarin , enoxaparin , clopidogrel , heparin ( use heparin central venous port maintenance acceptable ) . Ongoing bleed history clinically significant bleeding within last 6 month ( unless etiology prior bleed identify correct ) . Concurrent medication prolong QT interval ( include cisapride , erythromycin , antipsychotic tricyclic antidepressant , quinidine , procainamide , disopyramide , amiodarone sotalol ) , agent classify either `` Drugs Risk Torsades de Pointes '' `` Drugs Possible Risk Torsades de Pointes '' website www.torsades.org . Female subject pregnant breast feeding . Subjects reproductive potential willing use effective method contraception study ( first day 1 month study drug administration ) . Conditions may interfere QTc analysis : Allergy ECG electrode . Any condition impairs placement ECG electrodes interpretation ECGs ( include limit breast implant ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bladder Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Gastrointestinal Neoplasm</keyword>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Prostrate Cancer</keyword>
</DOC>